{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:57:58Z","timestamp":1791644278819,"version":"4.3.4"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Organization of Scientific Research"},{"name":"European Research Council Starting Researchers Grant"},{"DOI":"10.13039\/501100014106","name":"Stichting Stophersentumoren.nl","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014106","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["drupjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.drup.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T05:34:54Z","timestamp":1425620094000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":942,"special_numbering":"C","title":["Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment"],"prefix":"10.1016","volume":"19","author":[{"given":"O.","family":"van Tellingen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Yetkin-Arik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"de Gooijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wurdinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2015.02.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drup.2015.02.002_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drup.2015.02.002_bib0015","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/1535-7163.MCT-12-0552","article-title":"Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents","volume":"11","author":"Agarwal","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/gt.2012.62","article-title":"Oncolytic measles virus strains have significant antitumor activity against glioma stem cells","volume":"20","author":"Allen","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0030","first-page":"1339","article-title":"Mouse breast cancer resistance protein (Bcrp1\/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein","volume":"63","author":"Allen","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijpharm.2012.06.025","article-title":"Drug delivery strategies for the treatment of malignant gliomas","volume":"436","author":"Allhenn","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drup.2015.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1126\/science.1206936","article-title":"The Hedgehog pathway promotes blood\u2013brain barrier integrity and CNS immune quiescence","volume":"334","author":"Alvarez","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.drup.2015.02.002_bib0045","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/glia.22575","article-title":"Glial influence on the blood\u2013brain barrier","volume":"61","author":"Alvarez","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.drup.2015.02.002_bib0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3171\/2012.10.PEDS12142","article-title":"Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children","volume":"11","author":"Anderson","year":"2013","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.drup.2015.02.002_bib0055","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2008.19.3789","article-title":"Blood\u2013brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience","volume":"27","author":"Angelov","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1528-1167.2005.66604.x","article-title":"Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain","volume":"46","author":"Aronica","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.drup.2015.02.002_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1634\/theoncologist.4-3-209","article-title":"New treatment strategies for malignant gliomas","volume":"4","author":"Avgeropoulos","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2015.02.002_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bpa.12082","article-title":"Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations","volume":"24","author":"Barua","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/jcbfm.2015.19","article-title":"Approaching complete inhibition of P-glycoprotein at the human blood\u2013brain barrier: an (R)-[11C]verapamil PET study","author":"Bauer","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drup.2015.02.002_bib0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/clpt.2011.217","article-title":"Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood\u2013brain barrier: a comparison with rat data","volume":"91","author":"Bauer","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 3","key":"10.1016\/j.drup.2015.02.002_bib0085","first-page":"iii25","article-title":"ABCG2 and MDR promote brainstem gliomagenesis and limit the efficacy of dasatinib in a diffuse intrinsic pontine glioma (DIPG) mouse model","volume":"16","author":"Becher","year":"2014","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13324","article-title":"Mfsd2a is critical for the formation and function of the blood\u2013brain barrier","volume":"509","author":"Ben-Zvi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drup.2015.02.002_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nano.2013.07.003","article-title":"Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma","volume":"10","author":"Bernal","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drup.2015.02.002_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/fon.09.135","article-title":"Future of convection-enhanced delivery in the treatment of brain tumors","volume":"6","author":"Bidros","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nurt.2009.04.004","article-title":"Novel drug delivery strategies in neuro-oncology","volume":"6","author":"Bidros","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drup.2015.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.23994","article-title":"Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx((R))\/Doxil((R)) \u2013 a cerebral open flow microperfusion pilot study","volume":"103","author":"Birngruber","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drup.2015.02.002_bib0115","first-page":"4432","article-title":"Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy","volume":"47","author":"Blasberg","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0120","first-page":"132","article-title":"Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study","volume":"13","author":"Bogdahn","year":"2011","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0125","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2006.06.014","article-title":"The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy","volume":"24","author":"Brandt","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drup.2015.02.002_bib0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2015.02.002_bib0135","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1227\/NEU.0b013e3182233e24","article-title":"Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan","volume":"69","author":"Bruce","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.drup.2015.02.002_bib0140","series-title":"Efflux Inhibitor Compositions and Methods of Treatment Using the Same","author":"Bunt","year":"2014"},{"key":"10.1016\/j.drup.2015.02.002_bib0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2010.09.001","article-title":"A comprehensive outlook on intracerebral therapy of malignant gliomas","volume":"80","author":"Buonerba","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2015.02.002_bib0150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.wneu.2011.05.056","article-title":"Intra-arterial delivery of bevacizumab after blood\u2013brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival","volume":"77","author":"Burkhardt","year":"2012","journal-title":"World Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0142-9612(98)00172-0","article-title":"Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders","volume":"20","author":"Cao","year":"1999","journal-title":"Biomaterials"},{"key":"10.1016\/j.drup.2015.02.002_bib0160","first-page":"401","article-title":"Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study","volume":"12","author":"Carpentier","year":"2010","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0165","first-page":"1423","article-title":"Primary brain tumors in adults","volume":"77","author":"Chandana","year":"2008","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.drup.2015.02.002_bib0170","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/jm9016637","article-title":"New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration","volume":"53","author":"Che","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2015.02.002_bib0175","first-page":"189","article-title":"Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts","volume":"15","author":"Chen","year":"2013","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0180","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0185","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3171\/2013.11.PEDS136","article-title":"Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas","volume":"13","author":"Chittiboina","year":"2014","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.drup.2015.02.002_bib0190","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1124\/jpet.105.099648","article-title":"Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood\u2013brain barrier","volume":"317","author":"Choo","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0195","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/00001756-200211150-00014","article-title":"Localisation of breast cancer resistance protein in microvessel endothelium of human brain","volume":"13","author":"Cooray","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.drup.2015.02.002_bib0200","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood\u2013brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2015.02.002_bib0205","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1073\/pnas.0805165106","article-title":"Wnt\/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis","volume":"106","author":"Daneman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2015.02.002_bib0210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nature09513","article-title":"Pericytes are required for blood\u2013brain barrier integrity during embryogenesis","volume":"468","author":"Daneman","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2015.02.002_bib0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3835(99)00182-2","article-title":"Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR","volume":"146","author":"de Bruin","year":"1999","journal-title":"Cancer Lett."},{"issue":"Suppl. 6","key":"10.1016\/j.drup.2015.02.002_bib0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1528-1167.2012.03702.x","article-title":"Inflammatory events at blood\u2013brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease","volume":"53","author":"de Vries","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.drup.2015.02.002_bib0225","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","article-title":"P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan","volume":"13","author":"de Vries","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0230","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1537-1891(02)00201-X","article-title":"Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood\u2013brain barrier","volume":"38","author":"Demeule","year":"2002","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.drup.2015.02.002_bib0235","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1474-4422(10)70181-2","article-title":"Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas","volume":"9","author":"Dhermain","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drup.2015.02.002_bib0240","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2015.02.002_bib0245","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-12-2481","article-title":"Phase I study of GRN1005 in recurrent malignant glioma","volume":"19","author":"Drappatz","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0250","doi-asserted-by":"crossref","first-page":"dju090","DOI":"10.1093\/jnci\/dju090","article-title":"Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy","volume":"106","author":"Duebgen","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2015.02.002_bib0255","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2015.02.002_bib0260","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0006-291X(02)00376-5","article-title":"A new multidrug resistance protein at the blood\u2013brain barrier","volume":"293","author":"Eisenblatter","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2015.02.002_bib0265","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/exnr.1996.0156","article-title":"Unlocking the blood\u2013brain barrier: a role for RMP-7 in brain tumor therapy","volume":"141","author":"Elliott","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drup.2015.02.002_bib0270","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6690450","article-title":"Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters","volume":"80","author":"Emerich","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2015.02.002_bib0275","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.disamonth.2011.08.020","article-title":"Malignant gliomas: diagnosis and treatment","volume":"57","author":"Ferguson","year":"2011","journal-title":"Dis. Mon."},{"key":"10.1016\/j.drup.2015.02.002_bib0280","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0285","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/cncr.21112","article-title":"Enhanced chemotherapy delivery by intraarterial infusion and blood\u2013brain barrier disruption in malignant brain tumors: the Sherbrooke experience","volume":"103","author":"Fortin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2015.02.002_bib0290","first-page":"672","article-title":"Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain","volume":"58","author":"Fung","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0295","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.drup.2015.02.002_bib0300","doi-asserted-by":"crossref","first-page":"CT216","DOI":"10.1158\/1538-7445.AM2014-CT216","article-title":"Abstract CT216: phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma","volume":"74","author":"Gaillard","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2407-12-99","article-title":"Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol","volume":"12","author":"Geletneky","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2015.02.002_bib0310","first-page":"45","article-title":"The blood\u2013brain and blood\u2013tumor barriers: a review of strategies for increasing drug delivery","volume":"2","author":"Groothuis","year":"2000","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0315","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000408227","article-title":"Regional blood flow and blood-to-tissue transport in five brain tumor models: implications for chemotherapy","volume":"27","author":"Groothuis","year":"1984","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0320","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00441-003-0825-y","article-title":"Astrocyte mediated modulation of blood\u2013brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts","volume":"315","author":"Hamm","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0325","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajpath.2012.06.030","article-title":"Mechanisms of glioma-associated neovascularization","volume":"181","author":"Hardee","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0330","doi-asserted-by":"crossref","first-page":"e48752","DOI":"10.1371\/journal.pone.0048752","article-title":"Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats","volume":"7","author":"Huo","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drup.2015.02.002_bib0335","doi-asserted-by":"crossref","first-page":"e24396","DOI":"10.1371\/journal.pone.0024396","article-title":"Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain","volume":"6","author":"Idema","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drup.2015.02.002_bib0340","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3171\/jns.1994.81.5.0752","article-title":"Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors","volume":"81","author":"Inamura","year":"1994","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0345","first-page":"123","article-title":"The Ommaya reservoir in chemotherapy for malignant disease in the CNS","volume":"7","author":"Jacobs","year":"1981","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0350","series-title":"Regional Therapy of Brain Tumors","author":"Jordan","year":"2007"},{"key":"10.1016\/j.drup.2015.02.002_bib0355","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.drudis.2008.09.005","article-title":"The targeted delivery of cancer drugs across the blood\u2013brain barrier: chemical modifications of drugs or drug-nanoparticles?","volume":"13","author":"Juillerat-Jeanneret","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2015.02.002_bib0360","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2015.02.002_bib0365","first-page":"2849","article-title":"Increased penetration of Paclitaxel into the brain by inhibition of P-glycoprotein","volume":"9","author":"Kemper","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 4","key":"10.1016\/j.drup.2015.02.002_bib0370","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2011.09.005","article-title":"Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments","volume":"38","author":"Kesari","year":"2011","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0375","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0380","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug\u2013drug interactions: important determinants of drug disposition and effects","volume":"65","author":"Konig","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drup.2015.02.002_bib0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-540-46091-6_10","article-title":"Targeted therapy and blood\u2013brain barrier","volume":"176","author":"Korfel","year":"2007","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0390","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-009-1332-5","article-title":"Dose\u2013response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood\u2013brain barrier using (R)-[(11)C]verapamil PET","volume":"37","author":"Kuntner","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.drup.2015.02.002_bib0395","first-page":"871","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0400","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0405","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/ALN.0b013e31818d8f28","article-title":"Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein","volume":"109","author":"Kurnik","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drup.2015.02.002_bib0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1602\/neurorx.2.1.73","article-title":"Active efflux across the blood\u2013brain barrier: role of the solute carrier family","volume":"2","author":"Kusuhara","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.drup.2015.02.002_bib0415","first-page":"806","article-title":"Molecular imaging of gliomas with PET: opportunities and limitations","volume":"13","author":"la Fougere","year":"2011","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0420","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS13-P6-11-05","article-title":"Abstract P6-11-05: ANG4043, a brain-penetrant anti-HER2 mAb increases survival in mice bearing intracranial BT-474 breast tumor cells","volume":"73","author":"Lachowicz","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0425","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","article-title":"Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation","volume":"9","author":"Lagas","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0430","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","article-title":"Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment","volume":"15","author":"Lagas","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.104.073320","article-title":"Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood\u2013brain barrier: a minor role of breast cancer resistance protein","volume":"312","author":"Lee","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0440","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3171\/jns.2004.100.3.0472","article-title":"Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I\/II clinical study","volume":"100","author":"Lidar","year":"2004","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0445","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1083\/jcb.200806024","article-title":"Wnt\/beta-catenin signaling controls development of the blood\u2013brain barrier","volume":"183","author":"Liebner","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2015.02.002_bib0450","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/cns.13.15","article-title":"Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux","volume":"2","author":"Lin","year":"2013","journal-title":"CNS Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0455","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","article-title":"ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0460","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1158\/1078-0432.CCR-12-3105","article-title":"Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues","volume":"19","author":"Lin","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0465","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/JNS-07\/07\/0190","article-title":"Real-time image-guided direct convective perfusion of intrinsic brainstem lesions: technical note","volume":"107","author":"Lonser","year":"2007","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0475","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-09-1510","article-title":"Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin","volume":"70","author":"Lun","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0480","first-page":"800","article-title":"The potential of theragnostic (1)(2)(4)I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma","volume":"16","author":"Luther","year":"2014","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0485","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00006123-199904000-00022","article-title":"Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors","volume":"44","author":"Machein","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.drup.2015.02.002_bib0490","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0495","doi-asserted-by":"crossref","first-page":"e26882","DOI":"10.4161\/tisb.26882","article-title":"Blood\u2013brain barrier regulation: environmental cues controlling the onset of barrier properties","volume":"1","author":"Mizee","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.drup.2015.02.002_bib0500","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1523\/JNEUROSCI.1338-12.2013","article-title":"Retinoic acid induces blood\u2013brain barrier development","volume":"33","author":"Mizee","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drup.2015.02.002_bib0505","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-010-0255-0","article-title":"Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study","volume":"101","author":"Mueller","year":"2011","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0510","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0515","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.301.3.838","article-title":"Regulation of blood\u2013brain tumor barrier permeability by calcium-activated potassium channels","volume":"301","author":"Ningaraj","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00690311","article-title":"Microvascular abnormalities in ethylnitrosourea (ENU)-induced rat brain tumors: structural basis for altered blood\u2013brain barrier function","volume":"59","author":"Nishio","year":"1983","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0525","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cdip.2006.06.007","article-title":"Molecular pathology of gliomas","volume":"12","author":"Nupponen","year":"2006","journal-title":"Curr. Diagn. Pathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0530","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood\u2013brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2015.02.002_bib0535","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.113.208959","article-title":"Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain","volume":"347","author":"Oberoi","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0540","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0545","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0550","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/dmd.108.024018","volume":"37","author":"Ose","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2015.02.002_bib0555","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood\u2013brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.drup.2015.02.002_bib0560","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drup.2015.02.002_bib0565","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00401-012-1066-5","article-title":"Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited","volume":"124","author":"Plate","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.drup.2015.02.002_bib0570","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood\u2013brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0575","first-page":"96","article-title":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","volume":"5","author":"Prados","year":"2003","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0580","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/B:NEON.0000013478.27604.01","article-title":"Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001)","volume":"66","author":"Rainov","year":"2004","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0585","first-page":"2157","article-title":"Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma","volume":"6","author":"Rand","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0590","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1152\/ajplegacy.1970.219.1.270","article-title":"Effect of concentrated solutions on blood\u2013brain barrier","volume":"219","author":"Rapoport","year":"1970","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drup.2015.02.002_bib0595","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1152\/ajplegacy.1972.223.2.323","article-title":"Testing of a hypothesis for osmotic opening of the blood\u2013brain barrier","volume":"223","author":"Rapoport","year":"1972","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drup.2015.02.002_bib0600","first-page":"214","article-title":"Pharmacological modification of bradykinin induced breakdown of the blood\u2013brain barrier, The Canadian journal of neurological sciences","volume":"13","author":"Raymond","year":"1986","journal-title":"Le journal canadien des sciences neurologiques"},{"key":"10.1016\/j.drup.2015.02.002_bib0605","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.02031-13","article-title":"Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract","volume":"58","author":"Robillard","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2015.02.002_bib0610","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3171\/2011.2.PEDS10407","article-title":"Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride","volume":"7","author":"Saito","year":"2011","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.drup.2015.02.002_bib0615","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2176\/nmc.52.531","article-title":"Convection-enhanced delivery: from mechanisms to clinical drug delivery for diseases of the central nervous system","volume":"52","author":"Saito","year":"2012","journal-title":"Neurol. Med. Chir."},{"key":"10.1016\/j.drup.2015.02.002_bib0620","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3171\/2009.11.JNS091052","article-title":"Poor drug distribution as a possible explanation for the results of the PRECISE trial","volume":"113","author":"Sampson","year":"2010","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0625","first-page":"90","article-title":"Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study","volume":"7","author":"Sampson","year":"2005","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0630","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3171\/2011.7.JNS101238","article-title":"Low-grade gliomas in adults","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0635","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.23450","article-title":"Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability","volume":"102","author":"Sane","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drup.2015.02.002_bib0640","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.113.055228","article-title":"The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain","volume":"42","author":"Sane","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2015.02.002_bib0645","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood\u2013brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.drup.2015.02.002_bib0650","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/mvre.1999.2188","article-title":"Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties","volume":"58","author":"Schlageter","year":"1999","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0655","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jneumeth.2014.09.020","article-title":"Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study","volume":"238C","author":"Sewing","year":"2014","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.drup.2015.02.002_bib0660","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/foc.2006.20.4.6","article-title":"The IL-4 and IL-13 Pseudomonas exotoxins: new hope for brain tumor therapy","volume":"20","author":"Shimamura","year":"2006","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.drup.2015.02.002_bib0665","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drup.2015.02.002_bib0670","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3171\/jns.2000.92.4.0599","article-title":"In vivo assessment of the window of barrier opening after osmotic blood\u2013brain barrier disruption in humans","volume":"92","author":"Siegal","year":"2000","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drup.2015.02.002_bib0675","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/bse0500179","article-title":"Mammalian multidrug-resistance proteins (MRPs)","volume":"50","author":"Slot","year":"2011","journal-title":"Essays Biochem."},{"key":"10.1016\/j.drup.2015.02.002_bib0680","first-page":"1210","article-title":"Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma","volume":"16","author":"Sonabend","year":"2014","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0685","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2005.11.011","article-title":"Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood\u2013brain barrier","volume":"138","author":"Soontornmalai","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.drup.2015.02.002_bib0690","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1389450043345489","article-title":"Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack","volume":"5","author":"Stein","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.drup.2015.02.002_bib0695","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.114.138404","article-title":"Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT\/CT in an orthotopic mouse model of human glioma","volume":"55","author":"Suzuki","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.drup.2015.02.002_bib0700","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/bjc.1997.408","article-title":"Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts","volume":"76","author":"Takamiya","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2015.02.002_bib0705","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00230349","article-title":"Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas","volume":"425","author":"Tanaka","year":"1994","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.drup.2015.02.002_bib0710","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00151247","article-title":"Interstitial chemotherapy for brain tumors: review","volume":"10","author":"Tomita","year":"1991","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006123-199707000-00011","article-title":"Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study","volume":"41","author":"Valtonen","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.drup.2015.02.002_bib0720","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1078-0432.CCR-10-1980","article-title":"High impact of Oatp1a\/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel","volume":"17","author":"van de Steeg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2015.02.002_bib0725","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/jpet.107.121178","article-title":"Region-specific overexpression of P-glycoprotein at the blood\u2013brain barrier affects brain uptake of phenytoin in epileptic rats","volume":"322","author":"van Vliet","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0730","article-title":"Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019","author":"Vecchio","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2015.02.002_bib0735","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1128\/JVI.00495-09","article-title":"Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma","volume":"83","author":"Verheije","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2015.02.002_bib0740","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-005-0172-7","article-title":"Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group","volume":"58","author":"Warren","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2015.02.002_bib0745","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of astrocyte\u2013vascular coupling and the blood\u2013brain barrier by invading glioma cells","volume":"5","author":"Watkins","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2015.02.002_bib0750","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2015.02.002_bib0755","first-page":"79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0760","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrn3060","article-title":"The neurobiology of gliomas: from cell biology to the development of therapeutic approaches","volume":"12","author":"Westphal","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drup.2015.02.002_bib0765","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/cgt.2011.2","article-title":"Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery","volume":"18","author":"White","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.drup.2015.02.002_bib0770","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1172\/JCI8267","article-title":"Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood\u2013cerebrospinal fluid barrier","volume":"105","author":"Wijnholds","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2015.02.002_bib0775","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1537-1891(02)00200-8","article-title":"Tight junctions of the blood\u2013brain barrier: development, composition and regulation","volume":"38","author":"Wolburg","year":"2002","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.drup.2015.02.002_bib0780","first-page":"20","article-title":"Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts","volume":"9","author":"Yamashita","year":"2007","journal-title":"Neurooncology"},{"key":"10.1016\/j.drup.2015.02.002_bib0785","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1748-717X-9-25","article-title":"Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors","volume":"9","author":"Yang","year":"2014","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.drup.2015.02.002_bib0790","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/jpet.104.068528","article-title":"Plasma membrane localization of multidrug resistance-associated protein (MRP) homologues in brain capillary endothelial cells","volume":"311","author":"Zhang","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764615000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764615000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T11:38:47Z","timestamp":1598787527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764615000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":158,"alternative-id":["S1368764615000126"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2015.02.002","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}